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Summary
Mutations in PERK (EIF2AK3) result in permanent neonatal diabetes as well as several other anomalies that underlie the hu-
manWolcott-Rallison syndrome, and these anomalies are mirrored in Perk knockout mice. To identify the cause of diabetes
in PERK-deficient mice, we generated a series of tissue- and cell-specific knockouts of the Perk gene and performed a de-
velopmental analysis of the progression to overt diabetes. We discovered that PERK is specifically required in the insulin-
secreting b cells during the fetal and early neonatal period as a prerequisite for postnatal glucose homeostasis. However,
PERK expression in b cells is not required at the adult stage to maintain b cell functions and glucose homeostasis. We
show that PERK-deficient mice exhibit severe defects in fetal/neonatal b cell proliferation and differentiation, resulting in
low b cell mass, defects in proinsulin trafficking, and abrogation of insulin secretion that culminate in permanent neonatal
diabetes.Introduction
Dysfunctions in b cells or insufficient b cell mass may result in
permanent neonatal diabetes, thus requiring lifetime insulin
therapy for survival. Mutations in a small number of genes are
associated with permanent neonatal diabetes, including insulin
promoter factor (Ipf-1/Pdx-1) (Stoffers et al., 1997), forkhead
box P3 (FoxP3) (Wildin et al., 2001), ATP-sensitive potassium
channel Kir6.2 (Kcnj11) (Gloyn et al., 2004), and glucokinase
(Gck) (Njolstad et al., 2001). These genes encode crucial factors
controlling the development and physiological functions of
b cells. The loss of expression of PERK, eIF2a kinase (EIF2AK3),
was recently identified as a new form of permanent neonatal di-
abetes associated with the human Wolcott-Rallison syndrome
(WRS) (Delepine et al., 2000). Perk KO (PKO) mice were gener-
ated (Harding et al., 2001; Zhang et al., 2002) and mirror all of
the major anomalies of the human WRS (Zhang et al., 2002).
PKO mice suffer from a multitude of metabolic and growth ab-
normalities including hyperglycemia, growth retardation, skele-
tal defects, atrophy of the exocrine pancreas, and liver dysfunc-
tions (Zhang et al., 2002). These defects are likely mediated
through the phosphorylation of eIF2a, PERK’s signature sub-
strate, because mutations of the regulatory phosphorylation
site of eIF2a results in similar defects (Scheuner et al., 2001).
Diminished serum insulin and low b cell mass correlate with
the onset of neonatal diabetes in PERK-deficient individuals.
The reason for insufficient b cell mass was unknown; it may be
caused by loss of PERK function in the b cells and/or other cells
and organs that support b cell growth and survival. For example,
insulin-like growth factor 1 (IGF-1) is known to promote b cell
proliferation and survival (Rhodes, 2000), and we found that
the severe postnatal growth retardation associated with PKO
was primarily due to a deficiency in IGF-1 (Li et al., 2003). To
resolve the cellular and developmental basis of diabetes as-
sociated with WRS, we generated a series of cell- and tissue-CELL METABOLISM 4, 491–497, DECEMBER 2006 ª2006 ELSEVIER INspecific Perk KO mice and a b cell-targeted transgenic mouse
rescuing PERK function and show herein that expression of
PERK during the fetal development of b cells is a prerequisite
for postnatal glucose homeostasis.
Results
Expression of PERK is required in b cells
during fetal development
Pancreas-specific (pcPKO) and endocrine pancreas-specific
(enPKO) PERK-deficient mice were generated, and, similar to
global Perk KO (PKO) mice (Figure 1A), hyperglycemia and low
b cell mass were seen in these mice (Figures 1B, 1E, and 1F).
Despite low serum insulin levels in neonatal PKO mice (10.2-
fold less than wild-type; p < 0.001 at P4; n = 8 PKO, n =
15 WT), these mice were hypoglycemic during the first
10 days, averaging 25% less serum glucose than normal (p =
0.10) before rapidly becoming hyperglycemic between P19
and P21 (Figure 1A). Liver dysfunctions may contribute to the
early hypoglycemia in PKO mice, as liver steatosis and highly
variable levels of stored glycogen have been observed (Y.L.
and D.R.C., unpublished data), which may in turn reduce liver
glucose output, a critical source of glucose for neonatal mice.
Moreover, the activity of glucose-6-phosphatase, a key enzyme
in glycogenolysis and gluconeogenesis, was significantly re-
duced (specific activity; WT = 158, PKO = 112, t test p < 0.01)
in the liver of P3–4 PKO mice. In contrast, pcPKO mice, which
have normal liver expression of PERK, exhibited increased
blood glucose levels at birth, averaging 51% higher (p = 0.01)
during the first 10 days, and escalated to frank diabetes at the
end of the neonatal stage (Figure 1B).
To determine whether b cell-specific expression of PERK is
sufficient for glucose homeostasis, we introduced a Perk trans-
gene under the control of the rat insulin promoter (bPerk) and
crossed this transgenic strain to the PKO mice. The bPerk;PKOC. DOI 10.1016/j.cmet.2006.11.002 491
S H O R T A R T I C L EFigure 1. PERK expression is required in b cells for
development of b cell mass and maintenance of glu-
cose homeostasis
A and B) Serum glucose levels of PKO (A) and
pcPKO (B) mice during neonatal and juvenile devel-
opment. Each data point is the mean of 3–24 mice.
In this and all other figures, error bars = SEM.
C–J) Wild-type mice (C, P18) exhibit normal islets
with a dominant core of b cells (green, insulin) and
mantle of a cells (red, glucagon), whereas PKO (D),
pcPKO (E), and enPKO (F) mice (P21–22) have very
low b cell mass and disrupted islet structure. bPKO
(G, P23) and bPerk;PKO (H, P23) mice exhibit normal
b cell mass and islet structure. At E16.5, b cell mass
(green, insulin) is apparently normal (I, PKO; J, WT)
as seen in n = 6 wild-type and PKO embryos.mice did not become hyperglycemic over their lifetime (n > 20)
and had normal b cell mass (Figure 1H) but displayed the other
non-b cell defects seen inPKOmice. Surprisingly, b cell-specific
PERK-deficient mice (bPKO) also did not become diabetic.
However, since the Cre recombinase in this strain is not ex-
pressed until initiation of b cell differentiation (circa E13.5), we
found that the majority of b cells retained the wild-type Perk
gene until after birth; by P4 and P13, a deletion efficiency of
64% and 95%, respectively, had been achieved (see Figure S1
in the Supplemental Data available with this article online). bPKO
mice have normal b cell mass (Figure 1G), exhibit normal glu-
cose tolerance (see below), and are euglycemic for their entire
life (n > 30). The period between the onset of bPerk transgene
expression at E13.5 (Figure S1) and the early neonatal period
(P1–4), when the majority of b cells become PERK deficient in
bPKO, delimits the essential developmental stage of PERK ex-
pression in the b cells (Figure S1). Thus, PERK expression in
b cells is not required postnatally in adult mice to maintain glu-
cose homeostasis, whereas its expression is a prerequisite in
nascent fetal b cells for postnatal glucose homeostasis.
Insufficient b cell mass results from low b cell
proliferation
At birth, PERK-deficient mice exhibited 2.8-fold less b cell mass
than normal (Figure 2A). This difference in b cell mass widened
progressively during the first three postnatal weeks as PKO
mice progressed to frank diabetes. b cell mass normally ex-
pands during late fetal and neonatal development (Kaung,
1994); however, it increased only 2-fold in PKOmice, compared492to a 20.3-fold increase in wild-type mice during this period (Fig-
ure 2A). No difference was observed in b cell size. The accumu-
lation of b cell mass in pcPKO mice showed a similar develop-
mental lag during the neonatal period, exhibiting 56% of
normal mass at P1 but only 13% of normal mass at P21 (data
not shown). Analysis of b cell death by TUNEL (Table S1) and
TEM (data not shown) during the neonatal period found no sig-
nificant difference in cell death. Moreover, major markers of ER
stress were not significantly induced in pcPKO neonatal islets
(Figure 2E) or purified fetal b cells (Table S2), and microarray
analysis of P2 islets failed to detect increases in ER stress and
apoptotic genes (Table S3).
b cell proliferation in PKO mice was reduced by more than 2-
fold beginning at E16.5 and extending through P8 (Figures 2B
and 2C), as estimated by BrdU incorporation or expression of
the proliferation factor Ki67. A quantitative model based upon
the observed b cell proliferation supports the conclusion that
most, if not all, of the observed difference in b cell mass at the
end of the neonatal period can be attributed to reduced prolifer-
ation in PKOmice (Figure 2D). Gene profiling was performed us-
ing mRNAs extracted from P2 neonatal islets. Of the 42 genes
that exhibited a 2-fold or greater decrease in expression in
PKOmice, 22 genes encoded cell-cycle or proliferation factors,
including genes with critical functions in G2 andM stages (Table
S3). The expression of cyclin A, CDK1, and TOP2A in indepen-
dent samples of P3 PKO islets was confirmed by qRT-PCR to be
significantly (p < 0.05) downregulated by 2-fold or more,
whereas the G1 cyclins D1, D2, and D3 as well as CDK4
mRNA expression were not significantly different.CELL METABOLISM : DECEMBER 2006
PERK controls b cell development and proliferationFigure 2. b cell mass fails to accumulate in PERK-
deficient mice due to reduced proliferation
A) b cell mass of WT and PKO mice during neonatal
development. Wild-type mice exhibit a 2.8-fold (p =
0.002) and 17.7-fold (p = 0.03) higher number of
b cells than PKO mice in early neonates (P1–3) and
early juvenile mice (P24), respectively. Estimates of
relative b cell mass were made based on Glut2
mRNA expression levels per b cell (see Experimental
Procedures). Sample size (WT, PKO): P1 (5, 3), P2
(3, 4), P7 (3, 3), P14 (2, 2), P24 (4, 3).
B) BrdU incorporation is significantly reduced in fetal
PKO b cells. Student’s t test, p = 0.032 at E16.5; p =
0.002 at E18. Sample size (WT, PKO): E16.5 (4, 4),
E18.5 (5, 5). Total number of b cells counted (WT,
PKO): E16.5 (203, 562), E18.5 (1524, 1282).
C) A proliferation marker, Ki67, is diminished in PKO
b cells during perinatal and postnatal periods. Sam-
ple size (WT, PKO): E18.5 (4, 5), P0 (6, 6), P2 (6, 2),
P8 (6, 4). Total number of b cells counted (WT,
PKO): E18.5 (2917, 1361), P0 (6187, 4448), P2
(5980, 787), P8 (4990, 1932).
D) Theoretical estimation of the increase in b cell
mass during neonatal development as a function of
observed proliferation rates.
E) The expression of Ins1, Pdx-1, and MafA mRNAs
is significantly reduced in pcPKO islets (p < 0.001
for Ins1 and Pdx-1, p < 0.01 for MafA, p < 0.05),
whereas none of the ER stress genes is significantly
induced. Wild-type, n = 4–6; pcPKO, n = 6–8.Differentiation of b cells is impaired
in PERK-deficient mice
During the earliest stage of b cell development (E13.5–16.5),
b cell mass increases by neogenesis from endocrine progenitor
cells prior to the onset of the proliferative phase at E16.5. The
number of b cells in PKO mice at E16.5 was normal (Figures 1I
and 1J), suggesting that neogenesis is not impaired. However,
expression of the insulin genes, the key markers of b cell differ-
entiation, and MafA, a regulator of Ins1 and Ins2 transcription
(Zhao et al., 2005), was significantly repressed throughout the
fetal period from E13.5 to E18.5 (Figure 3A). Insulin content
was reduced 2-fold in PKO mice throughout fetal development
(Figure 3B) prior to the period when a significant difference in
b cell mass is observed. At birth, insulin content increased dra-
matically in wild-type mice, whereas PKOmice showed a small
increase resulting in 6-fold less insulin content compared to
wild-type. Perinatal insulin content of pcPKO islets was also sig-
nificantly reduced at E17.5 by 2.4-fold (p < 0.01) and at P1 by
3.1-fold (p = 0.01), as was the expression of Ins1, MafA, and
Pdx-1mRNA (Figure 2E). In addition, the fraction of b cells con-
taining nuclear localization of PDX-1 was significantly reduced
by 24% (p < 0.02) in PKO mice at E18.5.CELL METABOLISM : DECEMBER 2006Proinsulin and GLUT2 are abnormally retained
in the ER of PERK-deficient b cells
At E18.5, 30%–40% of the PKO b cells exhibited a highly dis-
tended endoplasmic reticulum, compressed nuclei and mito-
chondria, and peripheral dispersion of insulin granules (Figures
4A–4C). The luminal domain of this distended ER had high elec-
tron density, suggesting abnormal retention of newly synthe-
sized proteins. In PKOmice, approximately 30%–40% of b cells
displayed a shift from perinuclear localization of proinsulin to the
entire cell cytoplasm (Figure 4E) and were abnormally associ-
ated with the ER (Figure 4P). We denote this phenotype as
funkER cells. In addition, the GLUT2 plasmamembrane glucose
transporter exhibited the same anomalous accumulation in the
ER (Figures 4J–4L), suggesting a general defect in ER functions
that results in abnormal retention of secreted and plasma mem-
brane proteins. The funkER b cells were first seen at E15.5,
where they represented 1%–2% of the total b cells in PKO
mice, and increased to 22% at E16.5, with peak frequency of
42% at E18.5 to P3. The funkER cells were also observed in
the pcPKO (Figure 4F) and enPKO mice (data not shown). The
frequency of the funkER cells declined in PKO and pcPKO
mice in the second and third postnatal weeks (Figure 4I) as these493
S H O R T A R T I C L EFigure 3. Insulin expression and secretion is ablated
in PERK-deficient mice
A) Expression levels of insulin, Glut2, and MafA
mRNAs are significantly reduced in PKO. Expression
levels were quantified using qRT-PCR and normal-
ized toGAPDH levels. The ratios of PKO to WT levels
are shown. Student’s t test, *p < 0.05, **p < 0.01,
***p < 0.001. Sample size (WT, PKO): E13–15.5 (6,
6), E16.5–P0 (11, 10), P2–4 (4, 4).
B) Insulin content of fetal and neonatal pancreata.
The insulin level was normalized to the total protein
concentration, expressed as ng of insulin per mg of
protein. Sample size (WT, PKO): E16.5 (12, 7),
E17.5 (18, 6), E18.5 (7, 3), P1 (11, 9), P5–7 (denoted
as P6) (8, 6).
C) Islets isolated from P14 PKO mice and P10
pcPKOmice show reduced glucose-stimulated insu-
lin secretion as compared to WT littermates. Islets
were treated with low glucose (2.8 mM) or high glu-
cose (16.7 mM), and secreted insulin was assayed
and normalized to the total insulin content. The ratio
of insulin secreted by islets treated with high glucose
versus low glucose is plotted for individual animals.
D) Glucose tolerance test of P30 bPKO mice (n = 6)
and wild-type littermates (n = 8).mice progressed to frank diabetes. Thus, a high frequency of
funkER b cells may contribute to the development of diabetes
but is insufficient to cause it, as the bPKO mice do not become
diabetic.
Glucose-stimulated insulin secretion is ablated
in PERK-deficient mice
Neonatal P14 islets of PKO and pcPKO mice (Figure 3C) ex-
hibited a substantial reduction in glucose-stimulated insulin se-
cretion (GSIS) although basal insulin secretion was normal. In
addition, the endocrine cells within the islets are disorganized,
with a-glucagon interdigitated within the core of the islet (Fig-
ures 1D–1F), and the b cells fail to develop the normal contigu-
ous plasma membrane junctions typical of adult b cells that ap-
pear as a cellular syncytium. As cell-cell contacts are important
for extracellular signaling and insulin secretion of b cells (Roche-
leau et al., 2006), the failure to develop a normal islet architec-
ture is likely a contributing factor to the absence of GSIS in
PERK-deficient mice.
Discussion
Diabetes associated with the loss of PERK expression in hu-
mans and mice was speculated to be due to a postnatal loss494of b cells through apoptotic cell death arising from a failure to
properly regulate the endoplasmic reticulum unfolded protein
response (UPR) (Delepine et al., 2000; Harding et al., 2001;
Zhang et al., 2002). This hypothesis arose from the finding that
PERK is activated by ER stress and plays a role in regulating
the UPR in cultured fibroblasts. Although this hypothesis has
been generally accepted, no evidence has been reported that
dysfunctions in the ER stress/UPR pathway are the underlying
cause of diabetes in PKO mice or WRS patients. Moreover,
we failed to detect an increase in the gene expression of the
key markers of the ER stress response, although we cannot ex-
clude the possibility that an ER stress response occurred but
evaded our concerted effort to detect it. Similarly, Lipson and
coworkers (2006) found that IRE1a, another mediator of the
ER stress response, positively regulates proinsulin synthesis
but does so independently of XBP-1, its major ER stress target.
Previously, enhanced cell death in the pancreas of PKOmice
was reported (Harding et al., 2001; Zhang et al., 2002) but was
not specifically localized to the b cells. We found no evidence
for increased b cell death during fetal and neonatal stages.
Moreover, we found that b cell mass is not lost but instead fails
to accumulate during the fetal and neonatal period, when it nor-
mally increases. This failure to accumulate b cell mass in PKO
mice was found to be due to a marked decrease in b cellCELL METABOLISM : DECEMBER 2006
PERK controls b cell development and proliferationFigure 4. A subpopulation of PERK-deficient b cells
exhibit anomalous accumulation of proinsulin and
Glut2 in the ER
A–C) A fraction of the b cells in PERK-deficient mice
exhibit highly distended, electron-dense ER lumina
as detected by TEM (B and C), which we denote as
funkER cells. (A) shows P2 wild-type; (B) and (C)
show P7 pcPKO. Scale bar = 5000 nm in (A) and
(B) and 500 nm in (C). The outline of a funkER cell
is highlighted in (B). The arrow in (C) points to dis-
tended ER.
D–I) The funkER cells can be identified by their ab-
normal proinsulin distribution pattern as revealed
by epifluorescence immunohistochemistry. Proinsu-
lin, red; insulin, green. In wild-type (D, P8), proinsulin
is localized in discrete packets in Golgi adjacent to
nuclei, whereas PKO strains exhibit a mixture of nor-
mal (green with light yellow specks) and abnormal
doughnut-shaped (red-orange) patterns (E, P1
PKO; F, P1 pcPKO; G, P3 bPKO; H, P30 bPKO; I,
2-month-old PKO). The proinsulin distribution is al-
most normal in P30 bPKO (H) and adult PKO (I) mice.
J–L) GLUT2 accumulates abnormally in the ER of
PKO b cells (J, E18.5 wild-type; K and L, E18.5
PKO). GLUT2, green; proinsulin, red.
M–P) The abnormal accumulation of proinsulin in
PERK-deficient b cells colocalizes with the ER chap-
erone protein GRP78/BiP. In wild-type b cells, BiP is
dispersed throughout the cytoplasm (M, WT BiP),
whereas proinsulin is located in perinuclear patches
associated with the Golgi (N, WT BiP/proinsulin). In
PKO b cells, BiP (red) is dispersed in the cytoplasm,
with increased amounts in funkER cells (O,PKOBiP),
and proinsulin (green) colocalizes with BiP (upper ar-
row in O and P) in funkER cells (P, PKO BiP/proinsu-
lin). Note that some PKO b cells show a normal pat-
tern of proinsulin distribution (two arrows at bottom
of P).proliferation. The deficiency in b cell proliferation is substantial
enough to explain the 10- to 20-fold difference in b cell mass
at the onset of diabetes.
Robust expression of insulin and MafA mRNA, synthesis and
accumulation of insulin in secretory granules, and the ability to
rapidly secrete insulin in response to glucose are hallmarks of
the differentiated state of b cells. We found that, at the earliest
stage of neogenesis, the expression of Ins1, Ins2, and MafA
mRNA and insulin content were depressed in PERK-deficient
b cells. As b cells mature during the perinatal period, they de-
velop the ability to respond to glucose and secrete insulin, and
this is dependent in part upon the development of highly struc-
tured islets with an inner mass of b cells forming a syncytium
(MacDonald and Rorsman, 2006). PERK-deficient b cells, how-
ever, fail to show normal GSIS in neonatal development and
do not develop a normal b cell syncytium or islet structure. In
addition, a significant fraction of b cells exhibit anomalous
accumulation of proinsulin and GLUT2 in the ER. Overall, theseCELL METABOLISM : DECEMBER 2006abnormal traits, which arise in nascent b cells during embryo-
genesis, show that PERK is required for the differentiation of
b cells and development of normal islet architecture. Many of
these traits are regulated by PDX-1 (Offield et al., 1996) and ex-
hibit reduced expression in PERK-deficient islets, suggesting
that PERK may be a key regulator of this critical developmental
factor.
Concordant with the role of PERK in regulating fetal b cell dif-
ferentiation and proliferation, we found that expression of PERK
is required during the fetal period in order to avoid postnatal di-
abetes. This finding is consistent with other forms of permanent
neonatal diabetes that arise from embryonic defects in the de-
velopment of the b cells. Moreover, we show that deletion of
the Perk gene after the early neonatal stage does not lead to di-
abetes, diminished b cell mass, or b cell dysfunction. PERK is
also required for early neonatal body growth through its regula-
tion of IGF-1 (Li et al., 2003). Similar to its regulation of b cell
functions, PERK relinquishes its regulation of body growth late495
S H O R T A R T I C L Ein neonatal development. Thus, PERK plays a critical role in the
transition from fetal to adult life as profound developmental and
metabolic changes occur.
Experimental procedures
Genetic strains
The PKO mice strains (Zhang et al., 2002) were congenic for C57BL/6J
or 129SvEvTac or were mixed background, and each strain exhibited all
of the defects described herein. To generate tissue- or cell-specific
PKOmice, the floxed Perk allele (Zhang et al., 2002) was crossed to the Cre-
deletor strainsRIP-Cre to generate bPKO,Ngn3-Cre to generate enPKO, and
Pdx-1-Cre to generate pcPKO. To rescue the expression of PERK in the
b cells of PKOmice, a Perk transgene under the control of the rat insulin pro-
moter (bPerk) was introduced into the PKO mice (Li et al., 2003). The
MIP-GFP transgene (Hara et al., 2003), which expresses GFP exclusively in
insulin-secreting b cells, was crossed into the PKO strains. b cells from the
MIP-GFP PKO strain were purified by fluorescence-activated cell sorting
(FACS) based upon GFP fluorescence.
Immunohistochemistry
Paraffin-embedded sections were subjected to immunohistochemistry using
the following antibodies: insulin (Linco Research); glucagon, GLUT2, and
GRP78/BiP (Santa Cruz); proinsulin (Ole D. Madsen, Beta Cell Biology Con-
sortium); BrdU (DAKO); Ki67 (BDBiosciences); NGN3 and NKX2.2 (University
of IowaDevelopmental Studies HybridomaBank); NKX6.1 (Michael German);
and PDX-1 (Christopher Wright). Appropriate secondary antibodies conju-
gated with Alexa Fluor 488 or 555 dye (Molecular Probes) were used to visu-
alize the labels. Fluorescence images were captured and analyzed with
a Nikon Eclipse E1000 and Image-Pro Plus (Phase 3 Imaging Systems).
For GLUT2/proinsulin double-labeling experiments, sequential scans were
made using an Olympus FV300 laser scanning confocal microscope and
FluoView 300 4.3b.
For proliferation analyses, postnatal mice or pregnant mice were injected
intraperitoneally (i.p.) with BrdU (100 mg/g body weight) and sacrificed after
10 hr (postnatal mice) or 4 hr (embryos). For cell-death analysis, the DeadEnd
Fluorometric TUNEL System (Promega) was used. For TUNEL/insulin dou-
ble-labeling experiments, after the last wash of the TUNEL procedure, the
sections were blocked in 5% horse serum (GIBCO) and incubated with pri-
mary antibody (insulin) for 1 hr at room temperature. Samples for TEM studies
were prepared and analyzed as described previously (Zhang et al., 2002).
Islet isolation and b cell purification
Islets were isolated using a modified Histopaque-1077 separation method
(Kitamura et al., 2001). After partial purification, islets were manually picked
under a dissection scope. For b cell purification, isolated islets or pancreata
were disassociated by trypsin (0.125% in PBS; 4 min at 37C) to release sin-
gle cells. The islet cells were fractionated by FACS using a Beckman Coulter
Elite ESP based on GFP fluorescence of the MIP-GFP transgene, specific
for b cells, resulting in two populations of cells: GFP+ (b cells) and GFP2
(non-b cells).
b cell mass
Total b cell number was estimated by dividing the total amount of Glut2
mRNA or Insulin-1 mRNA in whole pancreata by the estimated amount of
Glut2 or Insulin-1 mRNA per b cell, respectively. As these two genes are ex-
clusively expressed in the b cells in the pancreas, their expression level is
directly proportional to b cell mass. The amount of total pancreatic Glut2
and Insulin-1 mRNAs was determined by qRT-PCR for wild-type and PKO
mice at various time points of neonatal development. To determine the
amount of Glut2 and Insulin-1 mRNA per b cell, GFP-tagged b cells (MIP-
GFP transgene) were purified from wild-type and PKO neonatal mice by
FACS after the procedures of Senee et al. (2006) followed by a determination
of the quantity of Glut2 and Insulin-1 mRNAs per b cell by qRT-PCR. See
Supplemental Data for qRT-PCR methods and primer sequences. The high
degree of purity of isolated b cells (GFP+) derived from FACS was confirmed
by quantitatively analyzing mRNA expression of b cell-specific markers (Ins1,
Ins2, and Glut2) versus other endocrine pancreatic markers (glucagon, so-
matostatin, and PP), which showed that over 99% of the GFP+ cells were
b cells (data not shown).496To compare the observed increase in b cell mass during neonatal develop-
ment to that expected based on the observed b cell proliferation rates, we
calculated the expected accumulation in b cell number over time (Figure 4C)
as a simple mathematical function of the fraction of b cells expressing the nu-
clear protein Ki67 and the estimated time (14.9 hr) that it takes to complete
one cell cycle in rodent b cells (Bonner-Weir et al., 2004).
GSIS and determination of blood glucose and insulin content
Blood samples were obtained from the tail and were measured for glucose
concentration using the Accu-Chek or OneTouch Ultra glucometers. Insulin
concentrationswere determined by ELISA (Alpco) andwere normalized to to-
tal protein concentration. For studies of GSIS, isolated islets were first cul-
tured for 1 hr at 37C (5% CO2) in RPMI1640 medium containing 10% fetal
bovine serum and 5 mM glucose. The islets were then incubated at 37C
for 15 min in KRB-HEPES buffer (pH 7.4) with 1% bovine serum albumin
and 2.8 mM glucose, followed by incubation with the same buffer containing
either 2.8 or 16.8mMglucose for 30min at 37C. At the end of the incubation,
the islets were collected by centrifugation, and the supernatant was assayed
for secreted insulin, which was normalized to islet insulin content. Islet insulin
content was normalized to the total protein concentration. Glucose tolerance
tests were performed on mice fasted overnight and injected i.p. with 2 mg
glucose/g of body weight.
Supplemental data
Supplemental Data include Supplemental Experimental Procedures, three
tables, and one figure and can be found with this article online at http://
www.cellmetabolism.org/cgi/content/full/4/6/491/DC1/.
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